The experimental antibody cocktail President Trump received after he tested positive for COVID-19 is being studied at Willis-Knighton in Shreveport. Principal investigator Doctor Joseph Bocchini says there’s evidence that it can reduce the virus.
“It looks like it will potentially be a very effective approach for outpatient treatment of patients with COVID-19,” said Bocchini.
Bocchini says lab-grown antibodies are given to a patient to combat the virus from continuing to replicate within someone’s body. He says the antibodies are administered intravenously.
“Patients receive a single intravenous infusion of the monoclonal antibodies, it takes a little over an hour for that infusion to take place,” said Bocchini.
The treatment has been cited by experts as one of the most promising tools in combatting COVID-19.
Bocchini’s reaction to hearing the treatment was being administered to the President?
“It was encouraging that the medical staff felt this was a potential benefit for the President who had been admitted to the hospital,” said Bocchini.
Comments